Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Insider Sells $648,688.78 in Stock

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) insider James C. Hamilton sold 32,729 shares of the firm’s stock in a transaction that occurred on Monday, January 6th. The shares were sold at an average price of $19.82, for a total transaction of $648,688.78. Following the completion of the sale, the insider now directly owns 272,122 shares in the company, valued at $5,393,458.04. This represents a 10.74 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

Arrowhead Pharmaceuticals Trading Up 0.9 %

ARWR stock traded up $0.17 during trading on Tuesday, hitting $19.67. 1,197,900 shares of the company traded hands, compared to its average volume of 1,241,250. The company has a debt-to-equity ratio of 2.06, a quick ratio of 6.74 and a current ratio of 6.74. The company has a 50-day moving average of $21.03 and a 200-day moving average of $22.56. The firm has a market capitalization of $2.45 billion, a PE ratio of -3.92 and a beta of 0.97. Arrowhead Pharmaceuticals, Inc. has a 1 year low of $17.05 and a 1 year high of $39.83.

Institutional Trading of Arrowhead Pharmaceuticals

A number of institutional investors have recently made changes to their positions in ARWR. Values First Advisors Inc. bought a new stake in Arrowhead Pharmaceuticals during the 3rd quarter valued at $52,000. Meeder Asset Management Inc. increased its position in shares of Arrowhead Pharmaceuticals by 4,629.2% in the second quarter. Meeder Asset Management Inc. now owns 3,405 shares of the biotechnology company’s stock valued at $88,000 after acquiring an additional 3,333 shares during the period. Mirae Asset Global Investments Co. Ltd. raised its stake in shares of Arrowhead Pharmaceuticals by 21.3% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,496 shares of the biotechnology company’s stock valued at $88,000 after acquiring an additional 788 shares during the last quarter. Quantbot Technologies LP purchased a new stake in shares of Arrowhead Pharmaceuticals during the third quarter worth about $149,000. Finally, Quarry LP grew its stake in shares of Arrowhead Pharmaceuticals by 54.5% in the second quarter. Quarry LP now owns 8,500 shares of the biotechnology company’s stock worth $221,000 after purchasing an additional 3,000 shares during the last quarter. Hedge funds and other institutional investors own 62.61% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts have recently commented on the stock. Chardan Capital reissued a “buy” rating and issued a $60.00 price target on shares of Arrowhead Pharmaceuticals in a report on Thursday, December 12th. Piper Sandler reduced their target price on Arrowhead Pharmaceuticals from $62.00 to $45.00 and set an “overweight” rating on the stock in a research note on Wednesday, November 27th. StockNews.com raised Arrowhead Pharmaceuticals to a “sell” rating in a research note on Friday, December 20th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Arrowhead Pharmaceuticals in a research report on Monday, September 9th. Finally, Royal Bank of Canada reissued an “outperform” rating and set a $42.00 price objective on shares of Arrowhead Pharmaceuticals in a report on Thursday, September 26th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and six have given a buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $43.33.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.